Recently, Kawamura et al. showed the role of ABCG2 and ABCB1 on CPT-11 (irinotecan) distribution inside mouse brain [21] which could be harnessed to improve efficiency of aggressive gliomas treatment. This evidence concerns the gene ABCG2 and central nervous system cancer.